Proteintech, CL555-pdlo, ChromoTek anti-PD-L1 recombinant VHH, CoraLite® Plus 555

Size: 150ul CL555-pdlo targets PD-L1 in FC and IF applications and shows reactivity with Human samples. Specification Applications: FC, IF Reactivity: Human Conjugate: CoraLite® Plus 555 Type: Nanobody Class: Recombinant Host: Alpaca Affinity: Picomolar range, below the assay limit (biolayer interferometry) Molecular Weight: 13.887 kDa Form: Liquid Excitation/Emission Maxima Wavelengths: 554 nm / 570 nm RRID: AB_3661835 Storage Buffer: 500 mM NaCl, 10 mM HEPES pH 7.0, 5 mM EDTA, 0.09% sodium azide Storage Condition: Store at -20°C Background: PD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and C-like immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis. D-L1 is critical for the induction and maintenance of immune self-tolerance during infection or inflammation in normal tissues. The interaction of PD-L1 and its receptors is responsible for preventing auto-immune phenotypes and balancing the overall immune response in situations such as pregnancy or tissue allografts. The interaction between PD-L1 and PD-1 or B7.1 starts an inhibitory signaling cascade, which results in the decreased proliferation of antigen-specific T-cells and increased survival of regulatory T-cells (PMID: 15240681).